Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

321
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
321
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

British journal of haematology·2026
Same author

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Cooperating under social anxiety: EEG hyperscanning reveals heightened interbrain synchrony and ERP responses in socially anxious adolescents.

Acta psychologica·2026
Same author

Spinal and supraspinal mechanisms of chronic itch: from neuronal circuits to the neuro-immune-microbial axis.

Frontiers in medicine·2026
Same author

Design, synthesis and anti-inflammatory activity on N-(4-(pyridin-4-yloxy)phenyl)-1,4-dihydropyridazine-3-carboxamide derivative z18 for acute lung injury, sepsis and ulcerative colitis models in mice.

European journal of medicinal chemistry·2026
Same author

A Bioinspired Nanozyme Enables Glycoimmune Therapy via Precision Sialoglycan Trimming.

Angewandte Chemie (International ed. in English)·2026
Same journal

Targeted Delivery of Indole-3-Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8<sup>+</sup> T Cell-Mediated Immunotherapy Response in Bladder Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Pathological Copper Overload Reprograms SOD1 Activation via COMMD1 to Promote Senescence and Fibrosis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Bending-Resistant Intimate 3D Graphene-Metal Heterojunctions for Highly Sensitive and Robust Flexible Sensors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

A Pathology-Instructed Theranostic Platform with Mechanoadaptive and ROS-Powered Nanobreathing Functions for Precision Myocardial Repair.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Targeting p21-High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

A Ceramic Network for Hybrid Solid Electrolyte Lithium Metal Batteries.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.6K

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

Jingyuan Tong1, Di Wang1, Haoze Song1

  • 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|November 21, 2025
PubMed
Summary
This summary is machine-generated.

Essential thrombocythemia (ET) involves distinct mutations affecting hematopoietic stem cells (HSCs). This study reveals how JAK2, CALR, and MPL mutations, and triple-negative ET, alter HSC function and contribute to disease, offering new therapeutic targets.

Keywords:
CALRCXCR4MPLessential thrombocythemia (ET)myeloproliferative neoplasms (MPN)scRNA‐seqtriple negative ET

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

983
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

Related Experiment Videos

Last Updated: Jan 10, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.6K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

983
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Essential thrombocythemia (ET) is characterized by JAK2, CALR, or MPL mutations, or is triple-negative (TN).
  • The impact of specific driver mutations on hematopoietic stem cell (HSC) heterogeneity and ET pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the molecular features of HSCs across different ET subtypes using single-cell RNA sequencing.
  • To elucidate the role of driver mutations and HSC subset alterations in ET pathogenesis.

Main Methods:

  • Single-cell RNA sequencing (scRNA-seq) of HSCs from ET patients.
  • Detection of driver mutations (JAK2, CALR, MPL) within HSCs.
  • Transcriptional profiling and comparative analysis of HSC subsets.

Main Results:

  • MPL-mutated HSCs show aberrant metabolism; CALR-mutated HSCs exhibit active cell cycling.
  • JAK2V617F-mutated HSCs display enhanced megakaryocyte (Mk) priming and interferon (IFN) response.
  • A novel HSC subset in TN ET resembles driver-mutated HSCs; reduced CXCR4+ HSCs skew myeloid differentiation and accelerate ET onset.

Conclusions:

  • Specific driver mutations confer distinct molecular characteristics to HSCs in ET.
  • Altered HSC heterogeneity, particularly the loss of CXCR4+ HSCs, contributes to ET pathogenesis.
  • Findings suggest potential therapeutic strategies targeting HSC dysfunction in ET.